Consistent with these data, a combination of talazoparib and the panRAF inhibitor (panRAFi) LY3009120 had a synergistic cytotoxic effect on BRAF/MEKi double-resistant A375 melanoma cells (A375 RR; Fig. 4C; Supplementary Fig. S2B). The gene discussed is BRAF; the disease is melanoma.